The firm said that it slashed its GAAP EPS guidance and made a smaller cut to its non-GAAP EPS guidance in response to US tariffs and other geopolitical conditions.

The firm raised a total of $13.5 million in its Series A equity financing round, which will go toward growing and advancing its neurodegenerative disease testing business.

NEW YORK – Uppsala University spinout Readily Diagnostics is using technology built off 30 years of research as the basis of a point-of-care, instrument-free test that would detect and differentiate ...

Of the 30 companies on the list, 17 saw their stock prices decrease, 11 saw their share prices increase, and two had their stock prices remain flat.

NEW YORK – Eight German associations are calling for changes to be made to the European In Vitro Diagnostics Regulation (IVDR ...

The former True Health Diagnostics executives were accused of participating in a scheme that paid Texas physicians for blood test referrals.

NEW YORK – With its combination immunoassay and qPCR blood test, Mursla Bio intends to identify liver cancers earlier by detecting microRNA targets within extracellular vesicles. Last week, Mursla ...

With the certification from the NYS Clinical Laboratory Evaluation Program, the company said the test is now available throughout the US.

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

The firm reported on Tuesday that its diagnostics revenues rose 6 percent from a year ago while its biopharma lab services revenues rose almost 2 percent.

NEW YORK — Digital pathology firm Gestalt Diagnostics said on Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...